My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

127.49 -2.10 (-1.62%)
Streaming Delayed Price Updated: 12:25 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
3 Fierce Stocks That Are Screaming Buys in December
Here are three winners in the making. 
Via The Motley Fool
Jazz Caregiver Survey: CBD-Based Epidiolex Improves Seizure & Non-Seizure Outcomes In Patients With Severe Epilepsy
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) caregiver survey that showed a substantial proportion of caregivers... 
Via Benzinga
Biotech Space Offers Reward In 2023 Despite Economic Risks
Despite the economic headwinds, the mid-to long-term outlook for the biotech space remains strong, and investors who are able to take advantage of undervalued biotech stocks may be well-positioned for... 
Via Talk Markets
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that. 
Via MarketBeat
Q3 Proves To Be Another Tough Quarter For Cannabis
It’s been a tough year for cannabis investors and Q3 offered little relief. 
Via Talk Markets
Is Axsome Therapeutics Stock a Buy Now?
The company seems to be coming into its own. 
Via The Motley Fool
Why Shares of Zymeworks Rose 12.18% on Monday
The biotech stock's shares may have been pushed by a short squeeze. 
Via The Motley Fool
Why Zymeworks Stock Is Soaring Today
Investors applauded a major licensing deal with Jazz Pharmaceuticals. 
Via The Motley Fool
Goldman Sachs, Walmart And These 2 Stocks Insiders Are Selling
The Nasdaq Composite dropped around 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Want to Double Your Money? Buying These Stocks Could be a Genius Move
These stocks are undervalued considering their long-term growth potential. 
Via The Motley Fool
Prediction: This Growth Stock Could Double in 2023
The next year should be a busy one for this drugmaker. 
Via The Motley Fool
Three CBD Stocks to Dominate a Budding Industry
The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity. 
Via MarketBeat
Topics Cannabis
Analyst Bumps Up Price Target For Avadel Pharmaceuticals After Favorable Patent Ruling
Last Friday, Delaware District Court granted Avadel Pharmaceuticals plc's (NASDAQ: AVDL) motion to delist the ‘963 Xyrem REMS patent. 
Via Benzinga
Avadel Pharmaceuticals Announces Favorable Ruling Regarding Sleep Disorder Drug Patent
 
Via Benzinga
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
Innovative products and services could keep these companies growing. 
Via The Motley Fool
3 Top Cannabis Stocks to Buy in November
These solid performers are managing to grow revenue in a difficult environment. 
Via The Motley Fool
2 Dirt Cheap Growth Stocks to Buy and Hold for Years
In the long run, these stocks could deliver great returns. 
Via The Motley Fool
What 5 Analyst Ratings Have To Say About Jazz Pharmaceuticals
Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings: 
Via Benzinga
Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance. 
Via Benzinga
Why Axsome Therapeutics Stock Slipped Today
Investors traded out of the company following the latest earnings release, but only to a modest degree. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy for November
Catalysts lie ahead for these promising stocks. 
Via The Motley Fool
2 Marijuana Stocks That Are Set for a Comeback
Don't overlook these top stocks when investing in the marijuana space. 
Via The Motley Fool
Jazz Pharma's Zepzelca For Lung Cancer Flunked Confirmatory Trial, But FDA Will Not Pull Accelerated Approval
A petition was filed requesting that the FDA initiate proceedings to withdraw approval of all medications containing lurbinectedin, currently marketed under the brand Zepzelca by Jazz Pharmaceuticals... 
Via Benzinga
Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline
 
Via Benzinga
Why Is Zymeworks (ZYME) Stock Up Today?
Zymeworks (ZYME) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (JAZZ). 
Via InvestorPlace
Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These two durable companies can navigate the market downturn and beyond. 
Via The Motley Fool
3 Red-Hot Stocks That Could Continue to Beat the Market
Investors are betting on these companies' revenue growth prospects. 
Via The Motley Fool
3 Top Marijuana Stocks to Buy for the Long Haul
The three have the financial strength to benefit from increased cannabis sales and cannabis therapies. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.